MiMedx Group Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2012
2013
2014
2015
2016
Net Income before Extraordinaries
7,662.40
4,111.90
6,220.00
29,446.00
11,974.00
Depreciation, Depletion & Amortization
1,845.60
1,691.20
2,125.00
2,732.00
5,460.00
Other Funds
16.10
57.50
-
504.00
1,165.00
Funds from Operations
1,801.60
5,362.90
19,798.00
42,035.00
36,324.00
Changes in Working Capital
5,186.40
5,648.40
2,996.00
23,228.00
10,496.00
Net Operating Cash Flow
3,384.80
285.50
16,802.00
18,807.00
25,828.00
Capital Expenditures
582.90
3,025.40
3,152.00
6,678.00
7,111.00
Purchase/Sale of Investments
-
-
9,000.00
6,000.00
3,000.00
Net Investing Cash Flow
582.90
3,025.40
12,152.00
678.00
11,742.00
Issuance/Reduction of Debt, Net
427.10
-
117.00
117.00
132.00
Net Financing Cash Flow
6,609.90
40,634.20
2,146.00
36,225.00
8,181.00
Net Change in Cash
2,642.20
37,323.30
2,504.00
18,096.00
5,905.00
Free Cash Flow
3,967.80
2,622.00
14,244.00
12,980.00
19,559.00
Deferred Taxes & Investment Tax Credit
-
-
-
7,081.00
594.00
Net Assets from Acquisitions
-
-
-
-
7,631.00
Change in Capital Stock
7,053.20
40,691.60
2,029.00
35,604.00
6,884.00

About MiMedx Group

View Profile
Address
1775 West Oak Commons Court NE
Marietta Georgia 30062
United States
Employees -
Website http://www.mimedx.com
Updated 07/08/2019
MiMedx Group, Inc. is a biopharmaceutical company. It engages in the design, manufacture, and marketing of regenerative biomaterials products and tissue processing services for the wound care, surgical, sports medicine, ophthalmic and dental market categories. The company's allograft product families include dHACM family with AmnioFix, EpiFix and EpiBurn brands; Amniotic Fluid family with OrthoFlo brand; Umbilical family with EpiCord and AmnioCord brands; Placental Collagen family with CollaFix and AmnioFill brands; Bone family with Physio brand; and Skin family with AlloBurn brand.